I assume the slide deck will also state that ‘further clinical development of DEP-Irinotecan is justified’
But just who is going to pay for and conduct the necessary extensive and expensive Phase 3 trial given that Pfizer are disinterested in licencing despite years of Starpharma showing them trial data.
‘Starpharma's Dep Irinotecan combination cancer drug has shown to be superior to Onivyde’ ~ @antibotter
This type of misleading pumping just never stops. The forum still awaits your explanation for posting this.
